Table 2 Between-group comparisons at Week 8: effects of diabetes on cardiac function directly before commencement of TETA treatment

Body-weight (g)

440 (425–455)

319 (298–340) ^a

326 (305–347) ^a

< 0.0001

Blood glucose (mM)

5.1 (4.7-5.6)

29.5 (27.0-32.1) ^a

28.1 (25.3-30.8) ^a

< 0.0001

Heart Rate (bpm)

401 (391–411)

322 (311–332) ^a

343 (335–352) ^{a, b}

< 0.0001

LVM (mg)

776 (731–820)

687 (651–723) ^a

710 (668–751) ^a

0.006

LVM/BW (mg/g)

1.76 (1.68-1.85)

2.17 (2.01-2.33) ^a

2.19 (2.07-2.31) ^a

< 0.0001

CO (ml/min)

200 (194–206)

135 (127–144) ^a

135 (129–140) ^a

< 0.0001

CO/LVM (ml/min.mg)

0.26 (0.24-0.28)

0.20 (0.18-0.21) ^a

0.19 (0.18-0.20) ^a

< 0.0001

LVEF (%)

73.7 (71.0-76.4)

68.2 (67.0-69.5) ^a

66.3 (64.5-68.0) ^a

< 0.0001

LVEDV (μl)

679 (651–706)

617 (584–651) ^a

591 (572–610) ^a

< 0.0001

LVEDV/LVM (μl/mg)

0.88 (0.84-0.92)

0.90 (0.85-0.95)

0.84 (0.79-0.89)

NS

LVESV (μl)

179 (157–202)

196 (183–209)

199 (189–210)

NS

LVESV/LVM (μl/mg)

0.26 (0.24-0.29)

0.32 (0.31-0.33) ^a

0.34 (0.32-0.35) ^a

< 0.0001

Stroke Vol (μl)

500 (480–520)

421 (396–446) ^a

392 (374–411) ^a

< 0.0001

Stroke Vol/LVM (μl/mg)

0.65 (0.61-0.68)

0.61 (0.58-0.65)

0.56 (0.52-0.59) ^{a, b}

0.001